17347-32-9

Basic information

• Product Name: 6-BROMO-BENZO[B]THIOPHENE
• Synonyms: 6-BROMO-BENZO[B]THIOPHENE;6-bromobenzothiophene;6-Bromo-1-benzothiophene
• CAS NO: 17347-32-9
• Molecular Formula: C₈H₅BrS
• Molecular Weight: 213.09
• EINECS: 1312995-182-4
• Mol File: 17347-32-9.mol
• Article Data: 22

Chemical Properties

• Melting Point: 56.0 to 60.0 °C
• Boiling Point: 140°C/30mmHg(lit.)
• Flash Point: 125.99 °C
• Appearance: /
• Density: 1.649 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.704
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-BROMO-BENZO[B]THIOPHENE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-BENZO[B]THIOPHENE(17347-32-9)
• EPA Substance Registry System: 6-BROMO-BENZO[B]THIOPHENE(17347-32-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 17347-32-9(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Uses

6-Bromobenzo[b]thiophene is a reagent for the synthesis of aminobenzo[b]thiophene 1,1-dioxides as STAT3 inhibitors with antitumor activities being an attractive therapeutic target for cancer therapy.

InChI:InChI=1/C8H5BrS/c9-7-2-1-6-3-4-10-8(6)5-7/h1-5H

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 360576-01-8 6-bromo-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 6320-01-0 3-Bromothiophenol 
• 105191-64-8 6-Brombenzothiophen-2-carbonsaeure-ethylester 
• 17347-29-4 1-bromo-3-(2,2-diethoxy-ethylsulfanyl)benzene 
• 19296-69-6 1-bromo-3-[(2,2-dimethoxyethyl)sulfanyl]benzene 
• 737802-11-8 (rac)-6-bromo-2,3-dihydrobenzo[b]thiophen-3-ol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 101774-28-1 (5-bromo-2-cyano-phenylsulfanyl)-acetic acid 
• 79603-03-5 4-bromo-2-nitro-benzonitrile 
• 3996-39-2 [(3-bromophenyl)sulfanyl]acetic acid 
• 19075-58-2 6-bromo-1-benzothiophene-2-carboxylic acid 
• 90001-42-6 6-bromo-benzo[b]thiophen-3-ol 

Downstream Products

• 154650-81-4 benzo[b]thiophene-6-carbonitrile 
• 17347-34-1 benzo[b]thiophene-4-carbonitrile 
• 946427-88-9 6-bromo-benzo[b]thiophene-3-carboxylic acid ethyl ester 
• 1426082-46-3 1-(6-bromo-benzo[b]thiophen-2-yl)-2,2,2-trifluoro-ethanone 
• 1426082-13-4 6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-benzo[b]thiophene-3-carbaldehyde 
• 1426082-14-5 (6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-benzo[b]thiophen-3-yl)-methanol 
• 1426082-15-6 1-(6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-benzo[b]thiophen-3-yl)-propan-1-ol 
• 1426082-16-7 1-(6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-benzo[b]thiophen-3-yl)-2,2,3,3,3-pentafluoro-propan-1-ol 
• 1426082-19-0 dimethyl-(2-{4-[5-(3-propylsulfanyl-benzo[b]thiophen-6-yl)-4-pyridin-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-amine 
• 1426082-21-4 dimethyl-(2-{4-[5-(3-methylsulfanyl-benzo[b]thiophen-6-yl)-4-pyridin-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-amine 
• 1426082-17-8 C₂₈H₂₅F₃N₄O₂S 
• 1426082-18-9 C₂₈H₂₅F₃N₄O₂S 
• 1426082-20-3 dimethyl-[2-(4-{5-[3-(propane-1-sulfinyl)-benzo[b]thiophen-6-yl]-4-pyridin-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine 
• 1426082-22-5 (2-{4-[5-(3-methanesulfinyl-benzo[b]thiophen-6-yl)-4-pyridin-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-dimethylamine 

Relevant articles and documents

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

INHIBITORS OF THE KYNURENINE PATHWAY

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.